Crizotinib showed better outcomes (progression-free survival (PFS), partial response (PR)) in ALK-positive NSCLC compared to chemotherapy in phase 3 clinical trials (as a second- and first-line treatment agent). Here, ALK is linked to non-small cell lung carcinoma.